The latest update is out from Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ).
Hangzhou Tigermed Consulting Co., Ltd. announced a further change in the use of proceeds from its H Shares Offering in 2025, with a focus on expanding service offerings, funding acquisitions, repaying borrowings, and general corporate purposes. This strategic reallocation aims to enhance the company’s global expansion, diversify its services, and strengthen its market position.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a company based in China, operating in the clinical research industry. It provides a range of clinical trial solutions and clinical-related services, focusing on expanding its service offerings and capabilities to meet rising demands in both domestic and international markets.
YTD Price Performance: 7.10%
Average Trading Volume: 65
Technical Sentiment Signal: Hold
Current Market Cap: €5.05B
Learn more about 3347 stock on TipRanks’ Stock Analysis page.